Seeking Alpha on MSN33m
BioNTech to buy bispecific antibody developer Biotheus for up to $950MUnder the deal, BioNTech (BNTX) will pay $800M in cash and American depositary shares to acquire all of the issued share capital of Biotheus. In addition, Biotheus stockholders will be eligible to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback